Nuofeng Pharmaceutical (Chengdu)
Global pharmaceutical group focusing on complex formulations
About Nuofeng Pharmaceutical (Chengdu)
Zennova Pharmaceutical Group is a Cayman-registered international pharmaceutical company established in 2018 by founder, Chairman, and CEO Dahai Guo. The company operates with a strategic focus on 'China manufacturing, global R&D, and global market'. It concentrates on four main therapeutic areas: ophthalmology, virology, cardiovascular diseases, and oncology, with ophthalmology and oncology being its core strategic fields.
Zennova has established a significant global presence with R&D and production facilities in Chengdu, China, and R&D bases in New York and New Jersey in the US. The state-of-the-art manufacturing facility in Chengdu Tianfu International Biotown is designed to meet cGMP standards for the US FDA, EU EMA, and China. The company possesses proprietary drug development technology platforms, including Liquipuls™ and BioCarrier®, developed over two decades. Its product pipeline includes over 60 FDA-approved drugs for various conditions.
The company's business model integrates R&D, manufacturing, and sales. It aims to establish three parallel revenue streams: US R&D and production for US sales, China R&D and production for international sales, and China R&D and production for domestic sales. Zennova engages in strategic partnerships to expand its market reach. In June 2024, it partnered with Quagen Pharmaceuticals for contract manufacturing and international sales rights. A similar agreement was signed with AiPing Pharmaceuticals in March 2024 for international sales cooperation and supply chain integration. In July 2023, Zennova completed a Series B financing round of nearly 100 million yuan, led by Hengbao Holding, to be used for commercial production, market preparation, and new product development.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 14.3/100
- Business model
- Manufacturing
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jul 2023 | $14M | $55M | Guilin Hengbao Health Protection | ↗ |
| SERIES AEquity / VC | Aug 2021 | $0 | — | Dyee Capital | ↗ |
Growth signals
Latest recorded traffic for Nuofeng Pharmaceutical (Chengdu) is 650 monthly website visits, up 242.1% over the last three months.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Nuofeng Pharmaceutical (Chengdu) in its local ecosystem
The Nuofeng Pharmaceutical (Chengdu) office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Dyee Capital
Guilin Hengbao Health Protection
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nuofeng Pharmaceutical (Chengdu) on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nuofeng Pharmaceutical (Chengdu)’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.